six-month follow up of ctl019 for diffuse large b-cell lymphoma
Published 6 years ago • 74 plays • Length 5:07Download video MP4
Download video MP3
Similar videos
-
10:23
data from the juliet trial of ctl019 for relapsed or refractory diffuse large b-cell lymphoma
-
4:38
four cycles of chemotherapy as effective as six for diffuse large b-cell lymphoma
-
10:30
six-month analysis of tisagenlecleucel in stubborn form of lymphoma shows sustained responses
-
5:50
large b-cell lymphoma: zuma-1 trial
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
2:39
reduction of chemotherapy cycles for diffuse large b-cell lymphoma
-
3:04
pet-directed therapy for early-stage diffuse large b-cell lymphoma
-
11:04
lisocabtagene maraleucel demonstrates improvement over standard of care in 2l lbcl
-
26:29
what diffuse large b-cell lymphoma patients should receive therapy different from r-chop?
-
0:55
long-term follow-up of acalabrutinib in r/r mantle cell lymphoma
-
53:58
new options when diffuse large b cell lymphoma (dlbcl) doesn’t respond to treatment
-
5:51
latest results from juliet: tisagenlecleucel in adults with dlbcl
-
5:51
updated juliet results for tisagenlecleucel in dlbcl
-
3:10
axicabtagene ciloleucel in patients with refractory large b cell lymphoma
-
46:48
relapsed and refractory diffuse large b-cell lymphoma
-
7:14
redlamp 14: does routine imaging after dlbcl remission improve post-treatment survival?
-
1:02:28
update on car t cell therapy for diffuse large b-cell lymphoma | lrf webinars
-
9:25
fda approvals in large b-cell lymphoma and melanoma, priority reviews in cscc and nsclc, and more
-
3:51
long-term outcomes on tisagenlecleucel: 4 years in dlbcl and fl